Related Experiment Videos

Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and

P Hahnfeldt1, D Panigrahy, J Folkman

  • 1Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

Cancer Research
|October 16, 1999
PubMed

Insights

This study investigates anti-angiogenic therapies, revealing a balance between tumor growth and inhibition. It ranks inhibitors and identifies a limit to tumor size, offering insights into cancer therapy and tissue regulation.

Area of Science:

  • Oncology
  • Biophysics
  • Mathematical Biology

Background:

  • Tumor growth is regulated by a balance of pro-angiogenic and anti-angiogenic factors.
  • Angiogenic inhibitors like endostatin, angiostatin, and TNP-470 are crucial in cancer therapy.
  • Understanding tumor growth dynamics under inhibitor control is vital for clinical applications.

Purpose of the Study:

  • To experimentally and theoretically investigate the effects of endostatin, angiostatin, and TNP-470 on tumor growth.
  • To develop a quantitative theory for tumor growth under angiogenic control.
  • To rank the relative effectiveness of these angiogenic inhibitors.

Main Methods:

  • Experimental investigation of tumor growth dynamics.
  • Theoretical modeling of tumor growth under angiogenic stimulator/inhibitor control.
  • Quantitative analysis of inhibitor effectiveness.

Main Results:

  • A quantitative theory for tumor growth under angiogenic control was developed.
  • The relative effectiveness of endostatin, angiostatin, and TNP-470 was ranked.
  • An ultimate limitation to tumor size was identified due to a dynamic balance of angiogenic stimuli.

Conclusions:

  • Anti-angiogenic therapy can modulate the ultimate tumor size.
  • The developed framework has implications for tissue size regulation beyond cancer.
  • This research provides a clinically implementable theory for tumor growth control.

Related Concept Videos